The UAB Center for AIDS Research (CFAR) is one of the seven original Centers established by NIAID in 1988. It is recognized formally within the University as a department-level Research Center and is governed by a Constitution and By-Laws. The overall research goals of investigators in the Birmingham CFAR are to understand at both the molecular level and at the level of the infected individual the pathogenesis of HIV infection and to utilize this information in conjunction with investigator pursuing experimental therapeutics, vaccine development, and behavioral modification to interfere with this pathogenic process. The multidisciplinary base of the Center will ensure the rapid translation of fundamental knowledge about AIDS and its related disorders into these clinical treatment and prevention programs. In order to facilitate this process, the major objectives of the Center for AIDS Research are threefold: 1. To enhance ongoing outstanding research programs by facilitating interdisciplinary interactions, by providing critical shared resource facilities and by providing administrative and fiscal management support mechanisms for Center investigators. 2. To stimulate participation of existing junior and established faculty in research programs aimed at AIDS-related subjects. This will be accomplished through the continued administration of a peer-reviewed competitive Developmental Grant Program that will provide funding for both developmental and pilot grants. 3. To stimulate recruitment and program development efforts in AIDS- related areas. The Center has identified new program areas and will assist Departments and Divisions in the process of investigator recruitment. Thus we anticipate continue growth and development of AIDS- related research in the CFAR. The Center will be led Dr. Eric Hunter (Director) and by an Executive Steering Committee consisting of Dr. George Shaw (Deputy Director) and six Associate Directors, Drs. Beatrice Hahn (Basic Sciences and Program Development), Richard Whitley (Clinical Sciences), Michael Saag (Clinical Care and Experimental Therapeutics), Laura Levition (Prevention Sciences and Epidemiology), Jiri Mestecky (Vaccine Development, and John Secrist (Drug Discovery and Development). The Center is comprised of 79 Center members form 24 Divisions and Departments within the University funded by more than 250 grants and contracts. Seven Core Facilities are proposed (Clinical, Central Virus, Molecular Biology, DNA Sequence, FACS, Program Development and Administration) that will provide key support for this funded research base. From its inception, the UAB CFAR has played a pivotal role in stimulating and supporting basic and clinical AIDS research and linking the two through interdisciplinary research programs. This has been most evident in the Center's principal thematic areas of viral pathogenesis, experimental therapeutics, and vaccine development. The success of the UAB CFAR is reflected in the growth in extramural funding for AIDS- related research from $2.9 million in 1988 (annual direct costs) to $14.0 million in 1993 (annual direct costs), the increase in number of R01-type AIDS-related grants from 5 to 30 during this same period, and the number of AIDS-related publications by Center members in peer-reviewed scientific journals between 1988 and 1993 (in excess of 1,000). All of the major research efforts within the Center link basic and clinical research and together they utilize every shared facility supported by the CFAR Core grant.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027767-10
Application #
2667704
Study Section
Special Emphasis Panel (SRC (71))
Project Start
1988-03-30
Project End
1998-08-31
Budget Start
1998-03-01
Budget End
1998-08-31
Support Year
10
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Microbiology/Immun/Virology
Type
Schools of Dentistry
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Shi, Bi; Geng, Jianlin; Wang, Yin-Hu et al. (2018) Foxp1 Negatively Regulates T Follicular Helper Cell Differentiation and Germinal Center Responses by Controlling Cell Migration and CTLA-4. J Immunol 200:586-594
Peng, Binghao J; Carlson, Jonathan M; Liu, Michael K P et al. (2018) Antisense-Derived HIV-1 Cryptic Epitopes Are Not Major Drivers of Viral Evolution during the Acute Phase of Infection. J Virol 92:
Crockett, Kaylee B; Rice, Whitney S; Turan, Bulent (2018) Associations Between Multiple Forms of Discrimination and Tobacco Use Among People Living With HIV: The Mediating Role of Avoidance Coping. J Acquir Immune Defic Syndr 78:9-15
Moshiri, Niema; Mirarab, Siavash (2018) A Two-State Model of Tree Evolution and Its Applications to Alu Retrotransposition. Syst Biol 67:475-489
Tomalka, Amanda G; Resto-Garay, Ivelisse; Campbell, Kerry S et al. (2018) In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol 9:2552
Mai, Uyen; Mirarab, Siavash (2018) TreeShrink: fast and accurate detection of outlier long branches in collections of phylogenetic trees. BMC Genomics 19:272
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786
Ram, Daniel R; Manickam, Cordelia; Hueber, Brady et al. (2018) Tracking KLRC2 (NKG2C)+ memory-like NK cells in SIV+ and rhCMV+ rhesus macaques. PLoS Pathog 14:e1007104
Elion, Richard A; Althoff, Keri N; Zhang, Jinbing et al. (2018) Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 78:62-72
Rice, Whitney S; Logie, Carmen H; Napoles, Tessa M et al. (2018) Perceptions of intersectional stigma among diverse women living with HIV in the United States. Soc Sci Med 208:9-17

Showing the most recent 10 out of 955 publications